With new data now available for use of brentuximab in ALK positive, CD30 anaplastic large cell lymphoma, what is your first line regimen?

I would say in the light of ECHLON-II data with a PFS and OS advantage specifically in ALCL and Advanced stage ALK positive disease Brentuximab-CHP would be the most beneficial option and standard of care.